Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness and Safety of Rivaroxaban versus Warfarin in people with non‐valvular atrial fibrillation and diabetes

Trial Profile

Effectiveness and Safety of Rivaroxaban versus Warfarin in people with non‐valvular atrial fibrillation and diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs Rivaroxaban (Primary) ; Warfarin (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2018 New trial record
    • 16 Apr 2018 Results published in the Diabetic Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top